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Abstract
Although they share certain biological properties with nucleic acid based infectious agents, prions, the causative agents of
invariably fatal, transmissible neurodegenerative disorders such as bovine spongiform encephalopathy, sheep scrapie, and
human Creutzfeldt Jakob disease, propagate by conformational templating of host encoded proteins. Once thought to be
unique to these diseases, this mechanism is now recognized as a ubiquitous means of information transfer in biological
systems, including other protein misfolding disorders such as those causing Alzheimer’s and Parkinson’s diseases. To
address the poorly understood mechanism by which host prion protein (PrP) primary structures interact with distinct prion
conformations to influence pathogenesis, we produced transgenic (Tg) mice expressing different sheep scrapie
susceptibility alleles, varying only at a single amino acid at PrP residue 136. Tg mice expressing ovine PrP with alanine
(A) at (OvPrP-A136) infected with SSBP/1 scrapie prions propagated a relatively stable (S) prion conformation, which
accumulated as punctate aggregates in the brain, and produced prolonged incubation times. In contrast, Tg mice
expressing OvPrP with valine (V) at 136 (OvPrP-V136) infected with the same prions developed disease rapidly, and the
converted prion was comprised of an unstable (U), diffusely distributed conformer. Infected Tg mice co-expressing both
alleles manifested properties consistent with the U conformer, suggesting a dominant effect resulting from exclusive
conversion of OvPrP-V136 but not OvPrP-A136. Surprisingly, however, studies with monoclonal antibody (mAb) PRC5, which
discriminates OvPrP-A136 from OvPrP-V136, revealed substantial conversion of OvPrP-A136. Moreover, the resulting OvPrP-
A136 prion acquired the characteristics of the U conformer. These results, substantiated by in vitro analyses, indicated that
co-expression of OvPrP-V136 altered the conversion potential of OvPrP-A136 from the S to the otherwise unfavorable U
conformer. This epigenetic mechanism thus expands the range of selectable conformations that can be adopted by PrP, and
therefore the variety of options for strain propagation.
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Introduction
Prion-mediated phenotypes and diseases result from the
conformationally protean characteristics of particular amyloido-
genic proteins. The prion state has the property of interacting with
proteins in their non-prion conformation, thus inducing further
prion conversion. The prion phenomenon has been described for
a variety of different proteins involved in diverse biological
processes ranging from translation termination in yeast, memory
in Aplysia, antiviral innate immune responses [1], and most
recently the action of the p53 tumor suppressor [2]. Since the
prion and non-prion conformations have differing biological
properties, the net result of this replicative process is protein-
mediated information transfer, the characteristics of which vary
from prion to prion. The ubiquity of prion replication indicates
that this is a wide-ranging of means of information transfer in
biological systems.
In the case of mammalian neurodegenerative diseases the prion
state is pathogenic as well as transmissible. A hallmark of such
conditions is the inexorable progression of pathology between
synaptically connected regions of the central nervous system
(CNS), consistent with advancing cell-to-cell prion spread.
Experimental transmission in several settings has been convinc-
ingly demonstrated in the case of the amyloid beta (Ab) peptide
which features prominently in Alzheimer’s disease (AD), the
intracytoplasmic protein tau, also involved in AD as well as various
neurodegenerative diseases referred to as taopathies, and a-
synuclein, the primary constituent of Lewy bodies found in
Parkinson’s disease (PD) [1,3].
The prototypic and best-characterized prion diseases are the
transmissible spongiform encephalopathies (TSEs) of animals and
humans, including sheep scrapie, bovine spongiform encephalop-
athy (BSE), chronic wasting disease (CWD) of cervids, and human
Creutzfeldt-Jakob disease (CJD). TSEs result from conformational
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conversion of the host-encoded cellular form of the prion protein,
PrPC, to the corresponding prion, or scrapie form, PrPSc. Since
TSEs share numerous properties with nucleic acid-based patho-
gens, including agent host-range, stable strain properties, and the
ability to mutate and respond to selective pressure, early
researchers assumed a viral etiology for these diseases. While this
is not the case, the unequivocal infectivity of TSEs set these prions
apart. Their singular capacity to cause fatal neurodegeneration in
genetically tractable animal models, and the ability to propagate
and quantify infectivity, in vivo, in cell culture or cell-free
conditions, provide unparalleled settings to elucidate general
mechanisms and devise integrated therapeutic approaches for all
diseases involving conformational templating [4].
TSEs have long incubation periods ranging from months to
years, are invariably fatal, and currently incurable. While a variant
of CJD (vCJD) is unequivocally linked to prions causing BSE [5],
the zoonotic potential of other TSE’s remains uncertain. Whereas
all TSEs, including human genetic and sporadic forms, are
experimentally transmissible, most are naturally infectious and
frequently occur as unanticipated epidemics. Scrapie is one such
example, and several iatrogenic epidemics have been reported.
More than 1,500 sheep developed scrapie following administration
of a scrapie-contaminated vaccine [6]. A similar recent event led to
an ,20-fold increase in the rate of scrapie in Italy [7].
Prion strain properties and the primary structure of PrP are the
two major elements controlling prion transmission. Optimal
disease progression appears to occur when the primary structures
of PrPSc constituting the infectious prion, and substrate PrPC
expressed in the host are closely related [8–10]. Underscoring the
importance of primary structure on transmission, susceptibility
and disease presentation are strongly influenced by several PRNP
polymorphisms in humans and animals. For example, a strong
association between susceptibility/resistance to natural scrapie is
associated with the valine (V)/alanine (A) dimorphism at PrP
residue 136 [11]. Prion strains are classically defined by differences
in incubation times, and the neuropathological profiles they induce
in the CNS. Seminal studies of mink prions [12], as well as studies
of human prions in Tg mice [13] indicated that strain information
is enciphered within the tertiary structure of PrPSc. While this
remains the favored explanation for prion strain diversity, the
mechanism by which primary and higher order PrPC and PrPSc
structures interact to influence pathogenesis are not understood.
Our previous studies demonstrated that A at ovine PrP residue
136 is a component of the monoclonal antibody (mAb) PRC5
epitope [14]. This property allowed us to use PRC5 in this study to
distinguish OvPrP-A136 from OvPrP-V136, affording the oppor-
tunity to monitor allele-specific OvPrP conversion during prion
infection. To accomplish this, we engineered Tg mice expressing
either OvPrP-A136 or OvPrP-V136, as well as Tg mice expressing
both alleles in the same neuronal populations. Here, using a
combination of in vivo and in vitro approaches, we address the
mechanism by which this important disease susceptibility dimor-
phism influences scrapie strain-specific pathogenesis.
Results
Transgenic mice to assess the effects of the OvPrP A/
V136 dimorphism on scrapie pathogenesis
We created Tg mice expressing OvPrP encoding either A or V
at residue 136. Using semi-quantitative Western and immuno dot
blotting we ascertained that levels of expression in the CNS of
Tg(OvPrP-A136)3533+/2 and Tg(OvPrP-V136)4166+/2 mice
were close to that of PrP expressed in the CNS of wild type mice
(Fig. 1A).
Both lines of Tg mice tolerated these levels of expression without
spontaneously developing recognizable signs of disease (Table 1).
In contrast, Tg mice of both genotypes intracerebrally (ic)
inoculated with brain homogenates from scrapie-affected sheep
succumbed to the neurological effects of prion disease following
variable incubation periods (Table 1). Rapid disease onset
occurred following inoculation of Tg(OvPrP-V136)4166+/2 mice
with SSBP/1 prions [15,16], which consistently produced an
,130 d mean incubation time. While SSBP/1 also caused disease
in Tg(OvPrP-A136)3533+/2 mice, mean incubation times were
,230 to 280 d longer (Fig. 1B and Table 1). In contrast, CH1641
prions [17] induced disease in all inoculated Tg(OvPrP-
A136)3533+/2 mice with a mean ,310 d onset of disease,
whereas no disease was registered in Tg(OvPrP-V136)4166+/2
mice after .560 d. These distinct transmission profiles are
consistent with previously recognized strain differences between
SSBP/1 and CH1641 scrapie prions [17]. Consistent with this
notion, western blot analysis of proteinase K-treated brain extracts
of diseased Tg(OvPrP-A136)3533+/2 mice confirmed that the
molecular profiles which distinguish PrPSc constituting SSBP/1 and
CH1641 prions [18] were maintained upon transmission (Fig. 1C).
These results demonstrate that Tg(OvPrP-A136)3533+/2 and
Tg(OvPrP-V136)4166+/2 mice are capable of distinguishing
scrapie strain-specific transmission patterns, and in turn that these
properties are influenced by the A/V136 dimorphism.
The influence of the OvPrP A/V136 dimorphism on PrPSc
conversion kinetics, conformation, and CNS deposition
Previous studies revealed a positive correlation between PrPSc
conformational stability and the incubation times of mouse and
cervid prions [19,20], but not of hamster prions [21,22]. We
performed guanidine denaturation treatments on PrPSc in brain
extracts of SSBP/1 infected Tg(OvPrP-V136)4166+/2 mice with
short incubation times and SSBP/1 infected Tg(OvPrP-
A136)3533+/2 mice with long incubation times. Analyses using
mAb 6H4 revealed distinct stability curves for OvPrPSc-V136 and
OvPrPSc-A136. The conformational stability of OvPrPSc-V136
was lower than OvPrPSc-A136 in the range of GdnHCl
concentrations between 1 and 2 M, (Fig. 2A) and GdnHCl1/2
values were 1.78 and 2.17 respectively. This confirmed that the
Author Summary
Prions are infectious proteins, originally discovered as the
cause of a group of transmissible, fatal mammalian
neurodegenerative diseases. Propagation results from
conversion of the host-encoded cellular form of the prion
protein to a self-propagating disease-associated confor-
mation. It is believed that the self-propagating pathogenic
form exists in a variety of subtly different conformations
that encipher prion strain information. Here we explored
the mechanism by which prion protein primary structural
variants, differing at only a single amino acid residue,
interact with prion strain conformations to control disease
phenotype. We show that under conditions of co-
expression, a susceptible prion protein variant influences
the ability of an otherwise resistant variant to propagate
an otherwise unfavorable prion strain. While this phenom-
enon is analogous to the expression of genetically-
determined phenotypes, our results support a mechanism
whereby dominant and recessive prion traits are epige-
netically controlled by means of protein-mediated confor-
mational templating.
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conformation of OvPrPSc-V136 produced in Tg(OvPrP-
V136)4166+/2 mice with rapid incubation times was less stable
than OvPrPSc-A136 produced in Tg(OvPrP-A136)3533+/2 mice
with longer incubation times. We refer to these conformations as
unstable (U) and stable (S), and to the rapidly and slowly
propagating prions composed of these conformers as SSBP/
1-V136(U), and SSBP/1-A136(S).
We then used histoblotting [23], a widely used method for
characterizing strain-specific differences in PrPSc distribution
[20,24], with mAb 6H4 to characterize OvPrPSc-A136(S) and
Figure 1. Characterization of transgenic mice expressing OvPrP-A136 and OvPrP-V136. A. Levels of transgene-expressed OvPrP in the
CNS were estimated by semi-quantitative western blotting using mAb 6H4. Amounts of total protein loaded (mg) in each sample are shown. Prnp0/0,
mice in which the PrP gene is disrupted; FVB, wild type mice. Estimates of expression levels, shown as a percentage (%) of that in FVB mice, are based
on densitometric analysis of signals from diluted samples. B. Survival curves of mice following inoculation with sheep SSBP/1 scrapie prions. Percent
(%) affected mice refers to numbers of mice within an inoculated cohort manifesting progressive clinical signs associated with prion disease. C.
Western blot analysis of PK-treated brain extracts of diseased Tg(OvPrP-A136)3533+/2 mice. SSBP/1 and CH1641 refer to mice inoculated with the
respective prions. I and R refer to sheep SSBP/1 or CH1641 inocula, and brain extracts from recipient mice respectively.
doi:10.1371/journal.ppat.1003692.g001
Table 1. Prion disease in transgenic mice expressing different ovine PrP scrapie susceptibility alleles.
Isolate Genotype Mean time to disease onset ± standard error of the mean (SEM), days
1
Tg(OvPrP-V136)4166+/2 Tg(OvPrP-A136)3533+/2 Tg(OvPrP-A/V)
2 None .552 (0/4) .429 (0/5)
2 SSBP/1 A136/V136 13262 (8/8) 412649 (6/6) 10565 (7/7)
3 SSBP/1 A136/V136 13361 (15/15) 367610 (15/15)
2 CH1641 A136/V136 .564 (0/6) 310621 (6/6)
1The number of mice developing clinical signs of prion disease divided by the original number of inoculated mice is shown in parentheses.
2Inoculations performed in Telling lab.
3Inoculations performed in Hunter lab.
doi:10.1371/journal.ppat.1003692.t001
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OvPrPSc-V136(U) deposition in the CNS. While OvPrPSc-A136(S)
had a punctate pattern of accumulation throughout the midbrain,
pons, and oblongata of slow incubation time Tg(OvPrP-
A136)3533+/2 mice (Fig. 3A), the neuroanatomical distribution of
OvPrPSc-V136(U) in the same sections of rapid incubation time
Tg(OvPrP-V136)4166+/2 mice was distinctly different, being more
intense and diffusely deposited than OvPrPSc-A136(S) (Fig. 3B).
Since Tg(OvPrP-A136)3533+/2 and Tg(OvPrP-V136)4166+/2mice
were both engineered using the same cosSHa.Tet cosmid vector
which drives expression from the PrP gene promoter, we conclude
that these differences are not the result of expression OvPrPC-A136
and OvPrPC-V136 in different neuronal populations.
The OvPrP A/V136 dimorphism influences strain-specific
PrP conversion in vitro
We used brain extracts of Tg(OvPrP-A136)3533+/2 or
Tg(OvPrP-V136)4166+/2 mice as sources of OvPrPC-A136 and
OvPrPC-V136 substrates for protein misfolding amplification
(PMCA) [25] using SSBP/1. While neither template spontane-
ously converted to PrPSc in the absence of seeded prions (Fig. 4A
and E), SSBP/1 reproducibly converted OvPrPC-V136 to
OvPrPSc-V136 during a single round of PMCA (Fig. 4C). In
contrast, conversion was not observed after a single round of
PMCA when OvPrPC-A136 was used as template (Fig. 4B and
Fig. 5A). We therefore used serial PMCA (sPMCA) [26] over 10
rounds to address whether conversion of OvPrPC-A136 to
OvPrPSc-A136 might be detected after prolonged replication.
Serial PMCA was performed in triplicate using equal amounts of
PrP from three different Tg(OvPrP-A136)3533+/2 or Tg(OvPrP-
V136)4166+/2 mouse brains using sheep SSBP/1 as seed. Apart
from a slight but consistent decrease between rounds two and five,
OvPrPSc-V136 production, detected using mAb 6H4, was
sustained throughout rounds one to 10 (Fig. 4C). As expected,
mAb PRC5 failed to detect OvPrPSc-V136 (Fig. 4G). In contrast,
Figure 2. Analyses of PrPSc in the brains of SSBP/1 infected mice. In A and C, densitometric analysis of immunoblots was used to measure
the amounts of protease-resistant OvPrPSc as a function of GdnHCl concentration. The dose-response curve was plotted using a Gaussian non-linear
least-square fit. Each point is the mean value derived from densitometric quantification of PK-resistant PrP in three diseased mouse brains. Error bars
correspond to standard errors of the mean. A. Conformational stability analysis using mAb 6H4 of OvPrPSc-A136(S) in Tg(OvPrP-A136)3533+/2 mice
(red line), OvPrPSc-V136(U) in Tg(OvPrP-V136)4166+/2 mice (blue line), and total OvPrPSc in Tg(OvPrP-A/V136) mice (black line). Black asterisks
compare differences between OvPrPSc-A136(S) and total PrPSc in Tg(OvPrP-A136)3533+/2 and Tg(OvPrP-A/V) mice; blue asterisks compare differences
between OvPrPSc-A136(S) in Tg(OvPrP-A136)3533+/2 mice and OvPrPSc-V136(U) in Tg(OvPrP-V136)4166+/2 mice. C. Conformational stability analysis
using mAb PRC5 of OvPrPSc-A136(S) in Tg(OvPrP-A136)3533+/2 mice (solid line) and OvPrPSc-A136(U) in Tg(OvPrP-A/V136) mice (dashed line).
*P,0.05, **P,0.005, ***P,0.001. In B and D, representative immunoblots of PK-resistant PrP in the brains of three mice from each infected cohort of
Tg(OvPrP-A136)3533+/2, Tg(OvPrP-V136)4166+/2, and Tg(OvPrP-A/V136) mice using mAb 6H4 (B) and mAb PRC5 (C). Times of onset of disease for
analyzed mice are also provided. OvPrP-V136 is indicated by blue symbols and text; OvPrP-A136 is indicated by red symbols and text.
doi:10.1371/journal.ppat.1003692.g002
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OvPrPSc-A136 was undetectable with mAbs 6H4 or PRC5 until
round eight, after which levels decreased during rounds nine and
10 (Fig. 4B and F).
Forced templating of a dominant PrPSc conformation in
mice expressing both susceptibility alleles
Having established that Tg mice expressing OvPrPC-V136 and
OvPrPC-A136 propagate SSBP/1-V136(U) and SSBP/1-A136(S)
prions with relatively rapid and slow incubation times respectively,
we produced Tg(OvPrP-A/V136) mice expressing both OvPrPC-
A136 and OvPrPC-V136 and inoculated them with SSBP/1 to
examine whether disease developed with fast, slow or intermediate
kinetics. Although more rapid than the ,130 d onset of disease in
Tg(OvPrP-V136)4166+/2 mice (P= 0.0094), the mean 10565 d
onset of disease contrasted with the .400 d SSBP/1 incubation
times observed in Tg(OvPrP-A136)3533+/2 mice (Fig. 1B and
Table 1).
Stability assessments using mAb 6H4 showed that the denatur-
ation curves of OvPrPSc produced in the brains of diseased
Tg(OvPrP-V136)4166+/2 and Tg(OvPrP-A/V136) mice were
superimposable over most of the range of GdnHCl concentrations
(Fig. 2A), indicating that OvPrPSc produced in Tg(OvPrP-A/V)
mice shared the conformation of OvPrPSc-V136(U) produced in
SSBP/1 infected Tg(OvPrP-V136)4166+/2 mice. In accordance
with this notion, histoblotting using mAb 6H4 showed that the
neuroanatomical distribution of OvPrPSc(U) in the brains of
diseased Tg(OvPrP-A/V) mice mirrored the diffuse deposition of
the OvPrPSc-V136(U) conformer located in similar sections of
rapid incubation time Tg(OvPrP-V136)4166+/2 mice (Fig. 3C).
While the rapid SSBP/1 incubation times, and properties of the
converted PrPSc in diseased Tg(OvPrP-A/V) were consistent with
propagation of SSBP/1-V136(U) prions, remarkably, western
blotting of diseased Tg(OvPrP-A/V136) brain extracts with mAb
PRC5 revealed substantial conversion of OvPrC-A136 to OvPrPSc-
A136 (Fig. 2D). Densitometric comparisons of OvPrPSc levels using
mAbs 6H4 (Fig. 2B) and PRC5 (Fig. 2D) allowed us to estimate
relative conversion efficiencies of each allele product in the brains of
SSBP/1 infected Tg(OvPrP-A/V136) mice. Using samples from
diseased Tg(OvPrP-A136)3533+/2 mice probed with mAbs 6H4
and PRC5 as normalizing controls for differences in the affinities of
the two mAbs for OvPrP-A136, we estimated by Western or dot
blotting that OvPrPSc-A136 comprised ,45% of total PK-resistant
PrP in the brains of diseased Tg(OvPrP-A/V136) mice.
Figure 3. Representative OvPrPSc distribution in the CNS of diseased transgenic mice. OvPrP-V136 and OvPrP-A136 are indicated by blue
and red text respectively. Times of onset of disease (d) for individual mice analyzed in histoblots are provided. Sections through the midbrain, pons
and oblongata are shown for SSBP/1 infected Tg(OvPrP-A136)3533+/2 mice (A and D); Tg(OvPrP-V136)4166+/2 mice (B and E); and Tg(OvPrP-A/V)
mice (C and F). In panels G and H, sections were not treated with PK and show distribution of total PrP. Histoblots in panels A–G were probed with
mAb 6H4; histoblots in D–H were probed with mAb PRC5.
doi:10.1371/journal.ppat.1003692.g003
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We then used mAb PRC5 to determine the conformation of
OvPrPSc-A136 among total OvPrPSc produced in the brains of
diseased Tg(OvPrP-A/V136) mice. The 1.64 GdnHCl1/2 value
of OvPrPSc-A136 produced under these conditions was distinct
from that of OvPrPSc-A136(S) produced in long incubation time
Tg(OvPrP-A136)3533+/2 mice (GdnHCl1/2 = 2.11), and their
non-superimposable PRC5 denaturation curves were significant-
ly different in the range of 1.5–2.5 M GdnHCl (Fig. 2C). These
findings demonstrated that the conformation of OvPrPSc-A136
in rapid incubation time Tg(OvPrP-A/V) mice was distinct from
OvPrPSc-A136(S) produced in long incubation time Tg(OvPrP-
A136)3533+/2 mice. We refer to this novel conformation
as OvPrPSc-A136(U), and to the resulting prions as SSBP/
1-A136(U).
Histoblotting using mAb PRC5 confirmed the comparatively
limited and punctate distribution pattern of OvPrPSc-A136(S) in
the CNS of long incubation time Tg(OvPrP-A136)3533+/2 mice
(Fig. 3D) that we observed with mAb 6H4 (Fig. 3A). As expected,
OvPrPSc-V136(U) in the CNS of diseased Tg(OvPrP-
V136)4166+/2 mice was refractory to detection by mAb PRC5
(Fig. 3E). We probed histoblots of the CNS from diseased
Tg(OvPrP-A/V136) mice with mAb PRC5 to assess the
appearance and distribution of OvPrPSc-A136(U). In contrast to
the punctate deposits of OvPrPSc-A136(S) in long incubation time
Tg(OvPrP-A136)3533+/2 mice (Fig. 3A and D), OvPrPSc-
A136(U) in Tg(OvPrP-A/V136) mice (Fig. 3F) acquired a diffuse
deposition and a distribution pattern that was equivalent to
OvPrPSc-V136(U) in Tg(OvPrP-V136)4166+/2 mice (Fig. 3B).
Consistent with the co-expression of each allele in identical cell
populations of Tg(OvPrP-A/V) mice, spatial distributions of
6H4- and PRC5-reactive PrP coincided in all analyzed sections of
Tg(OvPrP-A/V) mice (Fig. 3G and H).
Figure 4. Detection of OvPrPSc by sPMCA. In A and E, the first two lanes of each panel correspond to brain extracts from Tg(OvPrP-A136)3533+/2
and Tg(OvPrP-V136)4166+/2mice respectively without PK treatment. A136, V136, and A136/V136 refer to substrates from Tg(OvPrP-A136)3533+/2mice,
Tg(OvPrP-V136)4166+/2mice, and mixtures of the two respectively. In B and F, the first lanes of each panel correspond to brain extracts from Tg(OvPrP-
A136)3533+/2 mice without PK treatment; in C and G, the first lanes of each panel correspond to brain extracts from Tg(OvPrP-V136)4166+/2 mice
without PK treatment; in D and H, the first lanes of each panel correspond to mixtures of brain extracts from Tg(OvPrP-A136)3533+/2 and Tg(OvPrP-
V136)4166+/2 without PK treatment. In B–D and F–H, three different brains, indicated by #1–#3 were used as sources of substrates. In each case, the
second lane of the second panel contains PK treated SSBP/1. Panels A and E are sPMCA using the indicated templates in the absence of a prion seed.
Numbers in black above each lane refer to the round of sPMCA. C refers to a control in which no SSBP/1 seed was added. In each case C, and all
numbered lanes were treated with PK. Blots were probed with mAbs 6H4 or PRC5 as indicated.
doi:10.1371/journal.ppat.1003692.g004
Epigenetic Dominance of Prion Conformers
PLOS Pathogens | www.plospathogens.org 6 October 2013 | Volume 9 | Issue 10 | e1003692
PMCA reproduces strain specific effects of one allele
product on another
To simulate the combined effects of OvPrP-A136 and OvPrP-
V136 on PrP conversion in Tg(OvPrP-A/V136) mice in vitro, we
mixed equal quantities of OvPrPC-A136 and OvPrPC-V136 in
PMCA reactions seeded with SSBP/1. Under these conditions,
similar to when OvPrPC-V136 was present in isolation (Fig. 4C),
we observed early, reproducible conversion to OvPrPSc in round
one (Fig. 4D). Probing of western blots with mAb PRC5 showed
that OvPrPSc-A136 was a component of this converted material
(Fig. 4H). Thus, similar to our observations in Tg mice, the
presence of OvPrPC-V136 induced the relatively rapid conversion
of OvPrPC-A136 to OvPrPSc-A136 by SSBP/1. Interestingly,
subsequent conversion of both OvPrPC-A136 and OvPrPC-V136
diminished in rounds two to five, ultimately becoming undetect-
able through rounds six to 10 (Figs. 4D and H).
SSBP/1 was originally produced from a pool of diseased sheep
brains from the positive selection line in the Neuropathogenesis
Unit (NPU) Cheviot sheep flock, and has subsequently been
passaged as a pool. We next compared the seeding properties of
SSBP/1 with those of SSBP/1-A136(S) or SSBP/1-V136(U)
prions derived from SSBP/1-infected Tg(OvPrP-A136)3533+/2
or Tg(OvPrP-V136)4166+/2 mice. We monitored conversion of
OvPrPC-A136 or OvPrPC-V136 templates every two hours for a
total of 12 h of PMCA. SSBP/1-V136(U) had the same PMCA
properties as SSBP/1: both SSBP/1 and SSBP/1-V136(U) prions
efficiently converted OvPrPC-V136 in isolation, but not OvPrPC-
A136 in isolation; when both templates were present in the PMCA
reaction, the presence of OvPrPC-V136 facilitated conversion of
OvPrPC-A136 to OvPrPSc-A136 by SSBP/1 or SSBP/1-V136(U)
prions (Figs. 5A and B). In contrast, SSBP/1-A136(S) prions
converted either OvPrPC-V136 or OvPrPC-A136 templates to
PrPSc when they were present in isolation, the latter being
unequivocally confirmed to be OvPrPSc-A136 using mAb PRC5
(Fig. 5C); however, in the presence of both templates SSBP/1-
A136(S) prion propagation was inhibited (Fig. 5C). The properties
of prions derived from Tg(OvPrP-A/V) mice differed from SSBP/
1, SSBP/1-A136(S) or SSBP1/-V136(U) prions. Like SSBP/1 and
SSBP/1-V136(U), prions passaged through these mice efficiently
converted OvPrPC-V136, but not OvPrPC-A136. However, unlike
Figure 5. PMCA using defined seeds and substrates. PMCA was performed for various times indicated. At each time point samples were either
amplified by sonication (A), or matching control samples (C) received no sonication, and were therefore not amplified. Brain homogenates from
healthy Tg(OvPrP-A136)3533+/2 and Tg(OvPrP-V136)4166+/2mice served as sources of OvPrP-A136, OvPrP-V136 or mixtures of the two. In A, samples
were seeded with sheep SSBP/1; in B, samples were seeded with brain extracts from diseased Tg(OvPrP-V136)4166+/2 mice [SSBP/1-V136(U) prions];
in C, samples were seeded with brain extracts from diseased Tg(OvPrP-A136)3533+/2 mice [SSBP/1-A136(S); in D, samples were seeded with extracts
from diseased Tg(OvPrP-A/V) mice. Samples labeled 12* received no seed. The first three lanes of each immunoblot were loaded with the substrate(s)
for each PMCA reaction, not treated with PK; the corresponding seed, not treated with PK; and, the same seed treated with PK. All other samples were
digested with PK. Western blots were probed with mAbs 6H4 and PRC5 as indicated.
doi:10.1371/journal.ppat.1003692.g005
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SSBP/1 and SSBP/1-V136(U), such prions failed to facilitate
conversion of OvPrPC-A136 in the presence of OvPrPC-V136
(Fig. 5D).
Discussion
Novel transgenic mouse models for analysis of the
OvPrP-A/V136 dimorphism
Previous studies described the production of Tg mice expressing
OvPrP, and reported their susceptibility to scrapie prions [27–32].
The most widely characterized models are tg338 mice expressing
OvPrP-V136 [31], and Tgov59 [33] or Tgov4 [29] lines
expressing OvPrP-A136. In the case of tg338 mice, the transgene
was comprised of a bacterial artificial chromosome insert of
125 kb of sheep DNA, while in the case of Tgov59 and Tgov4
mice the neuron specific enoloase promoter was used to drive
OvPrP expression. These lines are maintained on different
heterogeneous genetic backgrounds, and CNS expression levels
in tg338 mice are ,8- to 10-fold higher than wild type, while
Tgov59 and Tgov4 lines each over express OvPrP-ARQ at levels
,2- to 4-fold higher than those found in sheep brain. Spontaneous
neurological dysfunction has been reported in Tg lines over
expressing OvPrP [27,31].
Tg(OvPrP-A136)3533+/2 and Tg(OvPrP-V136)4166+/2 mice
express transgene-encoded PrP, either slightly lower, or slightly
higher than PrP levels normally expressed in the CNS of wild
type mice. Since Tg(OvPrP-A136)3533+/2 and Tg(OvPrP-
V136)4166+/2 lines were produced using the cosSHa.Tet cosmid
vector which drives expression from the PrP gene promoter [34],
we expected expression of OvPrPC-A136 and OvPrPC-V136 in
identical neuronal populations, and therefore that both alleles are
co-expressed in the same cells of Tg(OvPrP-A/V) mice. Finally,
other than variable transgene insertion loci, both lines are
otherwise sygeneic on an inbred Prnp0/0/FVB background.
Previous studies reported on Tg mice expressing OvPrP with V
at 136, referred to as Tg(OvPrP)14882+/2 mice, that were also
produced in a Prnp0/0/FVB background using the cosSHa.Tet
cosmid vector [32]. However, in that study, comparable Tg mice
expressing OvPrP-A136 were not reported. Median SSBP/1
scrapie incubation times in Tg(OvPrP)14882+/2mice were 75 d,
and this line expresses OvPrP at levels only slightly higher than
Tg(OvPrP-V136)4166+/2 mice. While we exercise caution when
comparing results from mice produced by different groups, the
otherwise similar properties of Tg(OvPrP)14882+/2 and
Tg(OvPrP-V136)4166+/2 mice suggest that even slight differences
in the levels of transgene expression can have significant effects on
prion incubation time.
A clear link to codon 136 genotype and susceptibility/resistance
to different sheep scrapie isolates has been described in multiple
previous studies. Importantly, the influence of residue 136 on the
transmission of SSBP/1 and CH1641 prions in Tg(OvPrP-
A136)3533+/2 and Tg(OvPrP-V136)4166+/2mice is in accordance
with the properties of these isolates in sheep of various genotypes
[17]. Generally, increased susceptibility to scrapie is associated with
expression of OvPrP-V136, with A/A136 being the most resistant,
and V/V136 the most susceptible genotypes. In the case of SSBP/1
incubation periods are ,170 days in V/V136 sheep, while
transmission to A/A136 sheep is relatively inefficient, with no
disease recorded after .1000 days [35]. While SSBP/1 eventually
transmits to Tg(OvPrP-A136)3533+/2 mice with incubation times
exceeding 400 days, the general effects of the A/V136 dimorphism
on SSBP/1 transmission observed in sheep are recapitulated
in Tg(OvPrP-A136)3533+/2 and Tg(OvPrP-V136)4166+/2 mice
(Table 1). Similarly, CH1641, which propagates efficiently in
A/A136 sheep [35], preferentially propagates in Tg(OvPrP-
A136)3533+/2 mice (Table 1). In previous studies, CH1641
transmitted to TgOvPrP4 mice with an ,250 d mean incubation
time [36].
Although SSBP/1 incubation times are prolonged in A/V136
compared to V/V 136 sheep [35], in our studies incubation times
were shorter in Tg(OvPrP-A/V) than in Tg(OvPrP-V136)4166+/2
mice. While the condition of A/V136 heterozygosity has not been
previously modeled in Tg mice, this difference may result from
double the levels of transgene expression in Tg(OvPrP-A/V) mice
compared to Tg(OvPrP-A136)3533+/2 and Tg(OvPrP-
V136)4166+/2 mice. Tg(OvPrP-A/V136) mice were derived by
mating Tg(OvPrP-A136)3533+/+ with Tg(OvPrP-V136)4166+/+
mice, and therefore express greater total levels of OvPrP than
Tg(OvPrP-A136)3533+/2 and Tg(OvPrP-V136)4166+/2 mice
(Fig. 1A). Since the levels of OvPrP-V136 are equivalent in
Tg(OvPrP-V136)4166+/2 and Tg(OvPrP-A/V) mice, and we
show that OvPrP-A136 also becomes available for conversion, this
situation results in more available substrate for conversion. While
previous studies revealed an inverse correlation between transgene
expression levels and prion incubation times in Tg mice [8],
whether shorter incubation periods in Tg(OvPrP-A/V136) mice
than in Tg(OvPrP-V136)4166+/2 mice reflect overall differences
in PrPC expression levels remains uncertain. Differences in scrapie
pathogenesis between mice and sheep may also reflect the
influence of additional factors on disease in the natural host
including other PRNP polymorphisms [37,38], and different
involvements of the lymphoreticular system in sheep compared
to Tg mice.
Novel insights into the role of the A/V136 polymorphism
on strain selection and prion propagation
Our observations in Tg mice expressing individual allele
products suggested that rapid or prolonged SSBP/1 incubation
times in Tg(OvPrP-V136)4166+/2 and Tg(OvPrP-A136)3533+/2
mice respectively, reflected preferential conversion by SSBP/1
prions of OvPrPC-V136, rapidly producing a relatively unstable
OvPrPSc-V136(U) conformation that was diffusely deposited in the
CNS, compared to the slower conversion of OvPrPC-A136 to the
more stable OvPrPSc-A136(S) conformer which accumulated in
the CNS with a punctate pattern (Figs. 1–3). Our results are
consistent with the selection by the A/V136 dimorphism of SSBP/
1-A136(S) and SSBP/1-V136(U) prions in Tg(OvPrP-
A136)3533+/2 and Tg(OvPrP-V136)4166+/2 mice respectively.
We also show that PMCA recapitulates the influence of the A/
V136 polymorphism on the kinetics of SSBP/1 propagation
observed in Tg mice. The general conclusions from these studies
agree with previously published assessments of the mechanism of
conformational selection by distinct PrP primary structures
[39,40].
Based on the rapid SSBP/1 incubation times in Tg(OvPrP-A/
V136) mice, and shared conformational and distribution proper-
ties of OvPrPSc produced under these conditions with OvPrPSc-
V136(U) in Tg(OvPrP-V136)4166+/2 mice, we speculated that
OvPrP-A136 played no part during the propagation of SSBP/1
prions in Tg(OvPrP-A/V) mice. To address this we used mAb
PRC5 to exclusively monitor conversion of OvPrPC-A136.
Surprisingly, in contrast to its relatively slow conversion when
OvPrPC-A136 is expressed in isolation, co-expression with
OvPrPC-V136 in Tg(OvPrP-A/V136) mice facilitated rapid
conversion of OvPrPC-A136 to OvPrPSc-A136. The conformation
and diffuse CNS distribution of the resulting OvPrPSc-A136(U)
were equivalent to that of OvPrPSc-V136(U) and not OvPrPSc-
A136(S). Collectively, these results lead us to conclude that once
Epigenetic Dominance of Prion Conformers
PLOS Pathogens | www.plospathogens.org 8 October 2013 | Volume 9 | Issue 10 | e1003692
OvPrPSc-V136(U) is formed by conversion of OvPrPC-V136 by
SSBP/1 prions, the resulting unstable conformation induces rapid
conversion of OvPrPC-A136 to OvPrPSc-A136(U). That this
outcome is dependent on allele co-expression within the host is
demonstrated by the inability of the OvPrPSc-V136(U) conformer
to template OvPrPC-A136 when it is expressed in isolation.
Effects of OvPrP genotype on the propagation of scrapie prions
were not controlled during the isolation and propagation of SSBP/
1. Passage of SSBP/1 through Tg mice therefore allowed us to
generate prions composed solely of OvPrPSc-A136, OvPrPSc-
V136, or mixtures of both, and to draw additional conclusions
about the effects of the A/V136 dimorphism of prion propagation
using PMCA. Similar to our observations in Tg mice, SSBP/1
failed to convert OvPrPC-A136 to OvPrPSc-A136 by PMCA,
except in the presence of OvPrPC-V136 (Figs. 4 and 5). These
conversion properties are shared with SSBP/1-V136(U) prions,
but are distinct from SSBP/1-A136(S) prions, which show facile
conversion of both OvPrPC-V136 and OvPrPC-A136. These
results suggest that the SSBP/1-V136(U) is the dominant strain in
the natural SSBP/1 isolate. Multiple parameters could account for
this, including, but not restricted to, the effects of OvPrP genotype,
for example as a result of exclusive propagation in sheep of the
V136/V136 genotype, route of transmission in the infected sheep,
and differential/selective prion replication in the lymphoreticular
or central nervous systems of sheep. While our analyses indicate
the presence of both OvPrP-V136 and OvPrP-A136 alleles in
SSBB/1 (Table 1), it is important to note that SSBP/1 was derived
from a pool of sheep brains of undefined genotypes. PCR
approach precludes assessment of the extent to which alleles are
present in a sample, raising the possibility that the one or other
allele exists as a minor component in SSBP/1.
Our findings also suggest that PrPSc conformers may cross-inhibit
PrP conversion. In case of SSBP/1-A136(S) prions, the presence of
OvPrPC-V136 inhibited PMCA of OvPrPC-A136 (Fig. 5C). Also,
while SSBP/1 seeding of PMCA reactions containing mixtures of
OvPrPC-A136 and OvPrPC-V136 resulted in robust, reproducible
conversion to OvPrPSc-A136 as early as round one (Fig. 4H), total
PrPSc production was ephemeral with subsequent PrPSc formation
diminishing during rounds two to five, and conversion ultimately
becoming undetectable after round six. Since early PrPSc conversion
was sustained out to round 10 when OvPrPSc-A136 was not
produced (Fig. 4C and G), these results are consistent with inhibited
conversion of OvPrPC-V136 to OvPrPSc-V136 by OvPrPSc-A136.
While early (round one) PMCA conversion of PrPSc by SSBP/1
with either OvPrPC-V136 or mixtures of OvPrPC-V136 and
OvPrPC-A136 correlates with early onset of disease following
SSBP/1 infection of both Tg(OvPrP-V136) and Tg(OvPrP-A/
V136) mice, the subsequent inhibitory effects of OvPrPSc-A136
observed in PMCA would be impossible to detect in vivo, since
Tg(OvPrP-A/V) mice succumb to the lethal effects of early PrPSc
accumulation. Consistent with an inhibitory effect of OvPrPSc-
A136(U), prions from Tg(OvPrP-A/V) mice, while they converted
OvPrPC-V136 in isolation, failed to convert OvPrPC-A136 to PrPSc
in the presence of OvPrPC-V136 (Fig. 5D). Thus, the properties of
prions from this defined genetic background differ from SSBP/1.
We emphasize that, despite PCR data supporting the presence of
OvPrP-A136 alleles in this isolate, SSBP/1 was derived from sheep
of undefined OvPrP genotypes, rather than sheep with a defined
heterozygous OvPrP-A/V136 genotype.
Wider implications for the mechanism of prion
propagation
The inter-related effects of PrP primary and higher order struc-
tures on prion transmission were addressed in the Conformational
Selection Model, which proposed that strains are composed of a
range of PrPSc conformers, or quasi-species, and that only a subset of
PrPSc conformations is compatible with each PrP primary structure
[41]. While this model also took into account the effects of
polymorphic variation on prion propagation, it did so only in the
context of Tg mice expressing individual PrP allele products.
Transgenetic studies of the human codon 129 methionine (M)/
valine (V) polymorphism, and the analogous codon 132 M/leucine
(L) polymorphism in elk, indicated that these dimorphisms acted to
restrict or promote the propagation of particular prion strains
[39,40]. While the responses of Tg(OvPrP-A136)3533+/2 and
Tg(OvPrP-V136)4166+/2 mice are consistent with this notion, that
is selection of the U conformer by OvPrP-V136, and the S conformer
by OvPrP-A136, our unprecedented ability to analyze allele specific
conversion in infected Tg(OvPrP-A/A136) mice reveals a more
complex mechanism where mixtures of PrP variants may assist or
inhibit the propagation of strains under various conditions. For
example, SSBP/1 or SSBP/1-V136(U) prions facilitate conversion of
OvPrPC-A136 to OvPrPSc-A136(U) only in the presence of OvPrPC-
V136. Expressed in isolation, conversion of OvPrPC-A136 is favored
by the OvPrPSc(S) conformer. Our results demonstrate that co-
expression of different polymorphic forms of PrP, which would be the
norm in humans and animals, have profound effects on conforma-
tional selection of prion strains.
The results reported here address the molecular mechanisms
associated with the phenomenon of prion strain over-dominance
first observed by Dickinson and Outram [42], and subsequently
reported in other settings involving co-expression of long and short
incubation time PrP alleles [43]. While this phenomenon was
reconciled at the time by the assumption that TSEs were caused
by unidentified viral agents, our results now indicate that the
suggestion raised by those studies, namely that over-dominance
most likely resulted from physical interaction of allele products of
the scrapie incubation time locus during infection, was prescient.
Our results support a molecular mechanism involving cross
templating of an otherwise resistant allele product by a dominant
prion conformer, in this case OvPrPSc(U), which, we speculate,
involves physical association of otherwise ‘‘susceptible’’ and
‘‘resistant’’ allele products. Consistent with the observations
reported here, prion strain interference may also utilize similar
mechanisms of conformational selection in a host expressing
different PrP allele products infected with long and short
incubation period strains with different PrPSc conformational
stabilities [44,45].
In conclusion, we have used a combination of transgenic,
immunologic, and in vitro approaches to explore the mechanism
by which PrP primary structure variations and the conforma-
tions enciphered by different prion strains interact to control
TSE propagation. While our results support previous studies
indicating that PrP susceptibility polymorphisms, expressed in
isolation, act to restrict or promote the propagation of particular
prion conformers, we now show that under conditions of allele
co-expression a dominant conformer may alter the conversion
potential of an otherwise resistant PrP polymorphic variant to an
unfavorable prion strain. While such responses are analogous to
the phenotypic expression of genetically determined heritable
traits, dominant prion conformers act epigenetically by means of
protein-mediated conformational templating. By expanding the
range of possible conformations adoptable by a particular prion
protein primary structure, such interactive effects provide a
mechanism for promoting strain fitness, and, we speculate, strain
diversification. While the precise number scrapie strains in sheep
and goats remains uncertain, the description of at least 24
additional major sheep PRNP polymorphisms, and combinations
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All animal work was conducted according to the National
Institutes of Health guidelines for housing and care of laboratory
animals, and performed under protocols approved by the
Colorado State University Institutional Animal Care and Use
Committee, with approval number 11-2996A.
Transgenic mice
Sequences upstream of codon 44 of the OvPrP-A136 and V136
coding sequences were replaced with the corresponding sequence
from mouse PrP. The resulting constructs contained the OvPrP
coding sequence, except for addition of an extra residue for glycine
at codon 31, and the mouse PrP N-terminal signal peptide instead
of OvPrP signal peptide. Tg mice were generated by cloning the
OvPrP-A136 and OvPrP-V136 expression constructs into the
cosSHa.Tet cosmid vector [34], and microinjection of embryos
from inbred Prnp0/0/FVB mice. Tg founders were identified by
PCR screening of genomic DNA isolated from tail snips. Founder
mice were mated with inbred Prnp0/0/FVB mice, and generally
maintained with the transgene in the hemizygous state, with Tg
mice identified by PCR screening of genomic DNA from
weanlings. It was also possible to generate homozygous counter-
parts of each line, and Tg(OvPrP-A/V136) mice were generated
by crossing homozygous Tg(OvPrP-V136)4166+/+ mice with
homozygous Tg(OvPrP-A136)3533+/+ mice. We used immuno-
dot blotting and Western blotting with mAb 6H4 (Prionics,
Schlieren, Switzerland) to estimate the levels of OvPrP expression.
Tg mice subsequently shipped to and maintained in Edinburgh
were crossed onto the Prnp0/0/129Ola background [46].
Inocula
SSBP/1 originated as a homogenate of three natural scrapie
brains that were subsequently passaged mostly through Cheviot
sheep at the Neuropathogenesis Unit (NPU), Edinburgh UK
[15,16]. CH1641 is a naturally infected cheviot sheep from the
NPU flock [17]. The presence of OvPrP-A136 or OvPrP-V136
alleles in these samples was ascertained by restriction fragment
length polymorphism analysis of the PCR amplified PRNP coding
sequences.
Ten % mouse brain homogenates (w/v) were prepared in
phosphate-buffered saline (PBS) lacking calcium and magnesium
ions by repeated extrusion through 18- and 21-gauge needles.
Sheep brain homogenates (10%) in PBS were prepared by
repeated extrusion through 14-gauge, followed by 18- to 28-gauge
needles in PBS. Total protein content was determined by
bicinchonic acid (BCA) assay (Pierce Biotechnology, Inc.).
Determination of incubation times
Anesthetized mice were inoculated intracerebrally with 30 ml of
1% (w/v) brain extracts prepared and diluted in PBS.
General health was monitored daily. Onset of prion disease was
determined by observation of the progressive development of at
least three of the following clinical signs: truncal ataxia, loss of
extensor reflex, difficulty righting from a supine position, plastic
tail, head bobbing or tilting, kyphotic posture, circling and
paresis/paralysis. Animals were diagnosed when at least two
investigators agreed with the manifestation of these signs.
Incubation time is defined as the period between the time of
inoculation to the day on which subsequently progressive clinical
signs were initially recorded.
Analyses of PCR amplified PRNP coding sequences
Brain homogenates containing 500 mg protein were digested
with 400 mg/ml proteinase K (PK) in 0.4 M NaCl, 10 mM Tris–
HCl, pH 8.0, 2 mM EDTA, pH 8.0, and 2% SDS at 55uC
overnight. Genomic DNA was precipitated with isopropanol. The
partial OvPrP coding sequence was amplified by PCR with the
forward and reverse primers: 59-GGACAGGGCAGTCCTGGA-
39, 59-GTGATGCACATTTGCTCCACCACT-39. PCR prod-
ucts were purified with QIAquick Gel Extraction kit (QIAGEN
Science, MA, USA), digested with BspH I that only recognizes the
OvPrP-V136 allele, and the products were resolved on a 1.2%
agarose gel.
Protein misfolding cyclic amplification
Tg mice were perfused with PBS/5 mM EDTA. Ten % brain
homogenates (w/v) were prepared in PBS containing 150 mM
NaCl, 1.0% Triton X-100, and the complete TM cocktail of
protease inhibitors (Roche, Mannheim, Germany). Samples were
clarified by brief, low-speed centrifugation. Protein concentrations
of brain homogenates used as substrates for PMCA were adjusted
to contain equivalent amounts of OvPrP-A136 or OvPrP-V136,
based on the estimated relative levels of transgene expression.
Substrates in which OvPrP-A136 and OvPrP-V136 were mixed
were adjusted based on the estimated relative levels of transgene
expression, so that approximately equal amounts of each allele
product were present in the PMCA reaction. PMCA reactions
were performed as described previously [20,47] at a seed to
substrate ratio of 1:180. One cycle corresponded to 20 seconds of
sonication followed by 30 minutes incubation at 37uC. Controls
samples were incubated for the same duration at 37uC without
sonication. Amplified and control samples were digested with PK
at a final concentration of 0.33 mg/ml and analyzed on western
blots using mAbs 6H4 or PRC5.
Western blotting
Brain homogenates and cell lysates were digested with 100 mg/
ml or 30 mg/ml of PK respectively (Roche, Mannheim,
Germany) in cold lysis buffer for 1 h at 37uC. Digestion was
terminated with phenylmethylsulfonyl fluoride at a final concen-
tration of 2 mM. Samples were boiled for 10 min in the absence
of b-meracaptoethanol [14] and proteins were resolved by SDS-
PAGE and transferred to polyvinylidenedifluoride Immobilon
(PVDF)-FL membranes (Millipore, Billerica, USA). Membranes
were probed with primary mAbs followed by horseradish
peroxidase–conjugated anti-mouse secondary antibody (GE
Healthcare, Little Chalfont, UK). Protein was visualized by
chemiluminescence using ECL Plus (GE Healthcare, Piscataway,
USA) and an FLA-5000 scanner (Fujifilm Life Science, Wood-
bridge, USA).
Conformational stability assay
Brain homogenates containing 5 mg protein were incubated
with various concentrations of guanidine hydrochloride (GdnHCl)
in 96-well plates for 1 h at room temperature. Samples were
adjusted with PBS to a final of concentration of GdnHCl of 0.5 M
and transferred onto nitrocellulose (Whatman GmbH, Dassel,
Germany) using a dot blot apparatus. After two PBS washes, the
membrane was air-dried for 1 h, then incubated with 5 mg/mL
PK in 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.5% sodium
deoxycholate, 0.5% Igepal CA-630 for 1 h at 37uC. PK was
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inactivated with 2 mM PMSF. The membrane was incubated in
3 M guanidine thiocyanate in Tris-HCl, pH 7.8 for 10 min at
room temperature. After four washes with PBS, the membrane
was blocked with 5% nonfat milk in TBST for 1 h, and probed
with mAbs 6H4 (1:20,000) or PRC5 (1:5000) overnight at 4uC,
followed by HRP-conjugated goat anti-mouse IgG secondary
antibody. The membrane was developed with ECL Plus and
scanned with GE image quant 4000. The signal was analyzed with
ImageQuant TL 7.0 software.
Histoblotting
Histoblots were produced and analyzed according to previously
described protocols [23]. Images were captured with a Ni-
konDMX 1200F digital camera in conjunction with Metamorph
software (Molecular Devices).
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